Cardiff-based Antiverse raises $9.3M for AI antibody discovery

Cardiff is not the first city that comes to mind when discussing cutting-edge biotechnology. London, Cambridge, Boston — the familiar landmarks on the map of pharmaceutical innovation. But from the Welsh capital, a small company called Antiverse intends to overturn one of the most costly and slow processes in modern medicine — the development of therapeutic antibodies. This week, the startup announced the closing of a Series A round at $9.3 million, which gives it resources to transition from promising technology to actual preclinical programs.

The round was led by Soulmates Ventures, joined by Innovation Investment Capital and DOMiNO Ventures, as well as existing investors — DBW and Kadmos Capital. For a company founded in Cardiff and working at the intersection of machine learning and molecular biology, this is an important milestone: the funds will allow it to scale the computational platform and bring leading candidate molecules to the stage of in vivo testing, that is, on living organisms.

To understand the significance of what Antiverse does, it's worth recalling that antibodies are the foundation of a huge segment of modern pharmaceuticals. Monoclonal antibodies are used to treat cancer, autoimmune diseases, infections, and many other conditions. The global market for therapeutic antibodies is valued at more than $200 billion and continues to grow. However, the traditional process of their development remains painfully long and expensive. The search for a suitable antibody that will precisely bind to the target and at the same time be safe and stable can take years of laboratory work, and the cost of early stages is estimated in tens of millions of dollars.

This is where artificial intelligence comes into play. Antiverse's platform uses generative machine learning models to design antibodies de novo — that is, from scratch, without the need to test billions of variants in a test tube. The company's algorithms are trained on arrays of data about protein structure and antigen-antibody interactions, which allows them to predict which amino acid sequences are most likely to produce a molecule with the desired properties. Essentially, AI takes on the part of the work that previously required endless cycles of experimental screening and compresses it into a computational task.

Antiverse is far from the only player in this field. Over the past two to three years, the sector of AI-driven biological molecule development has experienced a real boom. Companies such as Absci, Generate Biomedicines, and BigHat Biosciences have attracted hundreds of millions of dollars for similar tasks. Google DeepMind's AlphaFold has radically changed the understanding of protein structure, and major pharmaceutical corporations — from Sanofi to Amgen — are actively forming partnerships with AI startups. Against this backdrop, $9.3 million looks modest, but for a company from Cardiff, it's a signal of serious intentions and, more importantly, confirmation of the technology's viability from professional investors.

The geographic context deserves special attention. The United Kingdom is consistently positioning itself as one of the leading hubs at the intersection of AI and life sciences. London's Francis Crick Institute, the Cambridge cluster, and now Welsh startups — the ecosystem is expanding beyond traditional centers. For Cardiff, Antiverse's success could become a catalyst: attracting venture capital to the region creates a precedent and infrastructure for the next companies.

However, the main question remains open. Computational design of antibodies is a beautiful idea, but real testing comes only when the designed molecules work in a living organism. The transition from computer model to successful preclinical trials — this is the barrier that separates promising technology from actual medicine. Antiverse now has the funding for this critical step, and the results of in vivo testing will show just how accurate the predictions of their AI platform are.

If everything works out, the company from Cardiff could become yet another proof that the future of pharmaceuticals is being created not only in laboratories with pipettes, but also on servers with GPUs. And for the industry as a whole, every successful case of AI-driven antibody development brings closer the moment when creating a new biological drug will take not a decade, but just a few years.